Idorsia Launches IMPACT-HTN with Stanford and Duke to Transform Hypertension Care

Idorsia Ltd, in collaboration with the Stanford Hypertension Center and Duke Heart Center, has announced IMPACT-HTN, a three-phase program designed to modernize the management of difficult-to-control hypertension. The initiative aims to generate real-world evidence, standardize decision-making, and develop AI-driven tools to better identify and manage high-risk patients.

Hypertension affects nearly half of U.S. adults, with uncontrolled cases doubling the risk of heart attack, stroke, kidney failure, and premature death. IMPACT-HTN will introduce digital care algorithms, personalized risk scoring, and early patient experience initiatives to address gaps in care. The program also highlights Idorsia’s Tryvio (aprocitentan), the first hypertension therapy in over 30 years to target a novel pathway, recently included in new ACC/AHA treatment guidelines.

By combining research, digital innovation, and novel therapies, Idorsia and its partners aim to redefine treatment standards and improve long-term outcomes for patients with difficult-to-control hypertension.

08-09-2025